

Date : 20.02.2017



To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

**SUBJECT:** Revised Quarterly Results for the Quarter Ending: 31-12-2016

Dear Sir/Madam,

With Reference to the Email dated: 17-02-2017, we here by enclose the Revised Results with a Copy of Limited review report of the Consolidated Results of the company.

This is for your information and record.

Thanking you

for TRIMURTHI LTD

  
**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2016.

**TRIMURTHI**  
GROUP

PART-I

(Rs. In Lakhs)

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR QUARTER III AND THREE MONTHS ENDED 31-12-2016**

Particulars	3 Months ended 31-12-2016	Preceding 3 months ended 30-09-2016	Corresponding 3 months ended 31-12-2015	Year to date figures for the current period ended 31-12-2016	Year to date figures for the previous year ended 31-12-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	79.73	39.76	0.00	277.29	0.00	0.00
Other Operating Income	24.57	14.09	24.08	48.78	65.79	93.00
<b>Total Operating Income(Net)</b>	<b>104.30</b>	<b>53.85</b>	<b>24.08</b>	<b>326.07</b>	<b>65.79</b>	<b>93.00</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods/Shares	69.93	63.38	0.00	306.72	0.00	0.00
c. (Increase)/Decrease in stock in trade and work in Progress	6.98	(24.81)	0.00	(34.28)	0.00	0.00
d. Employees Cost	5.11	5.43	5.76	15.82	15.57	23.94
e. Rent	0.35	0.75	0.60	1.85	1.10	1.65
f. Depreciation	3.46	2.35	10.97	8.71	25.54	33.60
g. Other Expenditure	2.47	5.52	3.18	15.46	13.53	27.78
<b>Total</b>	<b>88.31</b>	<b>52.63</b>	<b>20.51</b>	<b>314.28</b>	<b>55.74</b>	<b>86.96</b>
<b>Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>15.99</b>	<b>1.22</b>	<b>3.57</b>	<b>11.79</b>	<b>10.05</b>	<b>6.03</b>
4. Other Income	7.24	2.28	2.76	9.47	11.12	7.52
<b>5. Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3±4)</b>	<b>23.24</b>	<b>3.50</b>	<b>6.33</b>	<b>21.26</b>	<b>21.17</b>	<b>13.56</b>
6. Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5±6)</b>	<b>23.24</b>	<b>3.50</b>	<b>6.33</b>	<b>21.26</b>	<b>21.17</b>	<b>13.56</b>
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
<b>9. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>23.24</b>	<b>3.50</b>	<b>6.33</b>	<b>21.26</b>	<b>21.17</b>	<b>13.56</b>
10. Tax Expense (Including Deferred Tax)	6.70	0.14	4.95	6.81	5.34	3.73
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9±10)</b>	<b>16.54</b>	<b>3.36</b>	<b>1.38</b>	<b>14.45</b>	<b>15.83</b>	<b>9.82</b>
12. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
<b>13. Net Profit/ (Loss) for the period (11+12)</b>	<b>16.54</b>	<b>3.36</b>	<b>1.38</b>	<b>14.45</b>	<b>15.83</b>	<b>9.82</b>
14. Share Of Profit/(Loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
<b>16. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>16.54</b>	<b>3.36</b>	<b>1.38</b>	<b>14.45</b>	<b>15.83</b>	<b>9.82</b>
17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves, as per balance sheet of previous accounting year	334.09	334.09	324.27	334.09	324.27	334.09
<b>19. Earnings Per Share (EPS)</b>						
i. Basic & Diluted before extraordinary items (not annualised)	0.20	0.04	0.02	0.18	0.20	0.12
ii. Basic & Diluted after extraordinary items (not annualised)	0.20	0.04	0.02	0.18	0.20	0.12



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2016.

**TRIMURTHI**  
GROUP

**PART-II**

**SELECT INFORMATION FOR QUARTER III AND THREE MONTHS ENDED 31-12-2016**

Particulars	3 Months ended 31-12-2016	Preceding 3 months ended 30-09-2016	Corresponding 3 months ended 31-12-2015	Year to date figures for the current period ended 31-12-2016	Year to date figures for the previous year ended 31-12-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2900600	2849600	2849600	2900600	2849600	2849600
- Percentage of shareholding	35.81%	35.18%	35.18%	35.81%	35.18%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5199400	5250400	5250400	5199400	5250400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.82%	64.82%	64.19%	64.82%	64.82%
<b>B. Investor Complaints</b>	<b>3 Months Ended ( 31/12/2016)</b>					
Pending at the beginning of the quarter						
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

**Segment Reporting**

Particulars	Quarters ended			Period ended		Year ended
	31/12/2016 Unaudited	30/09/2016 Unaudited	31/12/2015 Unaudited	31/12/2016 Unaudited	31/12/2015 Unaudited	31/03/2016 Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	0.00	0.00
b. Financial Services	23.19	14.02	20.65	47.40	65.79	93.00
c. Investments	9.47	0.08	3.79	9.47	11.12	7.52
d. Trading in Shares	81.11	39.76	0.00	278.67	0.00	0.00
<b>Total</b>	<b>113.77</b>	<b>53.86</b>	<b>24.44</b>	<b>335.54</b>	<b>76.91</b>	<b>100.52</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>113.77</b>	<b>53.86</b>	<b>24.44</b>	<b>335.54</b>	<b>76.91</b>	<b>100.52</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	0.00	0.00
b. Financial Services	13.21	6.93	3.06	22.19	10.63	6.32
c. Investments	7.24	2.36	3.26	9.47	10.54	7.24
d. Trading in Shares	2.78	(5.79)	0.00	(10.41)	0.00	0.00
<b>Total</b>	<b>23.23</b>	<b>3.50</b>	<b>6.32</b>	<b>21.25</b>	<b>21.17</b>	<b>13.56</b>
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>23.23</b>	<b>3.50</b>	<b>6.32</b>	<b>21.25</b>	<b>21.17</b>	<b>13.56</b>
<b>3. Capital Employed</b>						
a. Pharma Business	0.00	2.24	9.18	0.00	9.18	-Nil-
b. Financial Services	653.06	471.51	962.94	653.06	962.94	842.40
c. Investments	179.34	359.69	172.98	179.34	172.98	301.69
d. Trading in Shares	326.14	308.57	0.00	326.14	0.00	0.00
<b>Total</b>	<b>1158.54</b>	<b>1142.01</b>	<b>1145.10</b>	<b>1158.54</b>	<b>1145.10</b>	<b>1144.09</b>

**Notes:**

- The above results have been taken on record by the board of directors of the company at their meeting held on 13-02-2017
- The financial results for the quarter ended 31-12-2016 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeably not allocated to the individual segment above.

Place : Hyderabad,  
Date : 13th February, 2017.

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2016

**TRIMURTHI**  
GROUP

(Rs. In Lakhs)

PART-I STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR QUARTER III AND THREE MONTHS ENDED 31/12/2016						
Particulars	3 Months ended 31-12-2016	Preceding 3 months ended 30-09-2016	Corresponding 3 months ended 31-12-2015	Year to date figures for the current period ended 31-12-2016	Year to date figures for the previous year ended 31-12-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	191.44	188.66	125.75	664.22	371.62	470.83
Other Operating Income	20.35	16.09	22.88	48.78	69.28	100.76
<b>Total Operating Income(Net)</b>	<b>211.79</b>	<b>204.76</b>	<b>148.63</b>	<b>713.00</b>	<b>440.90</b>	<b>571.59</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	12.42	Nil	Nil	12.42	Nil	Nil
b. Purchase of Traded Goods	172.28	181.12	102.56	642.55	327.23	411.89
c. (Increase)/Decrease in stock in trade and work in Progress	(6.27)	(17.99)	9.99	(42.52)	0.82	(0.64)
d. Manufacturing Expenses	1.37	Nil	Nil	1.37	Nil	Nil
e. Employees Cost	13.38	13.30	13.44	39.50	37.61	60.43
f. Depreciation	6.08	2.72	10.51	12.06	26.30	35.08
g. Other Expenditure	9.14	10.51	5.95	31.35	25.34	44.67
<b>Total</b>	<b>208.39</b>	<b>189.66</b>	<b>142.45</b>	<b>696.73</b>	<b>417.30</b>	<b>551.43</b>
<b>3. Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>3.39</b>	<b>15.10</b>	<b>6.17</b>	<b>16.27</b>	<b>23.60</b>	<b>20.16</b>
<b>4. Other Income</b>	15.56	3.94	2.79	19.78	11.25	13.23
<b>5. Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>18.95</b>	<b>19.04</b>	<b>8.96</b>	<b>36.05</b>	<b>34.85</b>	<b>33.39</b>
<b>6. Finance Cost</b>	0.23	0.00	0.00	0.23	0.00	0.06
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>18.72</b>	<b>19.04</b>	<b>8.96</b>	<b>35.82</b>	<b>34.85</b>	<b>33.33</b>
<b>8. Exceptional Items</b>	-Nil-	Nil	-Nil-	-Nil-	-Nil-	-Nil-
<b>9. Profit/ (Loss) from Ordinary activities before Prior period items and tax (7+8)</b>	<b>18.72</b>	<b>19.04</b>	<b>8.96</b>	<b>35.82</b>	<b>34.85</b>	<b>33.33</b>
<b>10. Prior period Items</b>	0.00	0.00	Nil	0.00	Nil	9.17
<b>11. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>18.72</b>	<b>19.04</b>	<b>8.96</b>	<b>35.82</b>	<b>34.85</b>	<b>24.16</b>
<b>11. Tax Expense (Including Deferred Tax)</b>	7.99	4.85	2.52	13.96	10.44	11.20
<b>12. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)</b>	<b>10.73</b>	<b>14.18</b>	<b>6.44</b>	<b>21.86</b>	<b>24.41</b>	<b>12.96</b>
<b>13. Extraordinary Items(Net Of Tax Expenses)</b>	Nil	Nil	Nil	Nil	Nil	Nil
<b>14. Net Profit/ (Loss) for the period (11+12)</b>	<b>10.73</b>	<b>14.18</b>	<b>6.44</b>	<b>21.86</b>	<b>24.41</b>	<b>12.96</b>
<b>15. Share of Profit/(loss) Of Associates</b>	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
<b>16. Minority Interest</b>	(0.01)	4.34	0.01	5.36	3.45	3.04
<b>17. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>10.74</b>	<b>9.84</b>	<b>6.43</b>	<b>16.49</b>	<b>20.96</b>	<b>9.91</b>
<b>18. Paid-up Equity Share Capital (Face Value of Rs.10/- each)</b>	810.00	810.00	810.00	810.00	810.00	810.00
<b>19. Reserves excluding revaluation reserves as per balance sheet of previous accounting year</b>	345.11	345.11	332.90	345.11	332.90	345.11
<b>20. Earnings Per Share (EPS)</b>						
<b>i. Basic &amp; Diluted before extraordinary items (not annualised)</b>	<b>0.13</b>	<b>0.12</b>	<b>0.08</b>	<b>0.20</b>	<b>0.26</b>	<b>0.12</b>
<b>ii. Basic &amp; Diluted after extraordinary items (not annualised)</b>	<b>0.13</b>	<b>0.12</b>	<b>0.08</b>	<b>0.20</b>	<b>0.26</b>	<b>0.12</b>



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLCO18956

**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2016



**TRIMURTHI**  
GROUP

**PART-II**

**Select Information for Quarter III and Three months Ended 31/12/2016**

Particulars	3 Months ended 31-12-2016	Preceding 3 months ended 30-09-2016	Corresponding 3 months ended 31-12-2015	Year to date figures for the current period ended 31-12-2016	Year to date figures for the previous year ended 31-12-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2900600	2849600	2849600	2900600	2849600	2849600
- Percentage of shareholding	35.81%	35.18%	35.18%	35.81%	35.18%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5199400	5250400	5250400	5199400	5250400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.82%	64.82%	64.19%	64.82%	64.82%
<b>Particulars</b>						
<b>B. Investor Complaints</b>	<b>3 Months Ended ( 31/12/2016)</b>					
Pending at the beginning of the quarter						
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

**Segment Reporting**

Particulars	Quarters ended			Period ended		Year ended
	31/12/2016	30/09/2016	31/12/2015	31/12/2016	31/12/2015	31/03/2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	101.51	150.90	121.62	380.96	371.62	478.60
b. Financial Services	23.19	14.09	27.01	47.40	69.28	93.00
c. Investments	12.90	(0.28)	2.79	12.90	11.25	13.23
d. Foods	12.85	0.00	0.00	12.85	0.00	0.00
e. Trading in Shares	81.11	39.76	0.00	278.67	0.00	0.00
<b>Total</b>	<b>231.56</b>	<b>204.48</b>	<b>151.42</b>	<b>732.78</b>	<b>452.15</b>	<b>584.82</b>
<b>Less: Inter Segment Revenue</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>Net Sales/ Income From Operations</b>	<b>231.56</b>	<b>204.48</b>	<b>151.42</b>	<b>732.78</b>	<b>452.15</b>	<b>584.82</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	(4.43)	20.59	(2.16)	18.93	11.17	19.26
b. Financial Services	9.39	23.40	7.82	22.19	13.00	2.41
c. Investments	9.85	(2.64)	3.29	9.47	10.68	12.94
d. Foods	(6.05)	1.69	0.00	(4.36)	0.00	0.00
e. Trading in Shares	9.97	(20.38)	0.00	(10.41)	0.00	0.00
<b>Total</b>	<b>18.73</b>	<b>22.67</b>	<b>8.96</b>	<b>35.82</b>	<b>34.84</b>	<b>34.60</b>
<b>Less:</b>						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>18.73</b>	<b>22.67</b>	<b>8.96</b>	<b>35.82</b>	<b>34.84</b>	<b>34.60</b>
<b>3. Capital Employed</b>						
a. Pharma Business	196.72	86.00	57.05	196.72	57.05	61.18
b. Financial Services	999.12	471.51	977.66	999.12	977.66	910.43
c. Investments	10.62	463.77	108.24	10.62	108.24	169.89
d. Foods	42.26	125.17	64.33	42.26	64.33	64.33
e. Trading in Shares	34.28	51.18	0.00	34.28	0.00	0.00
<b>Total</b>	<b>1283.00</b>	<b>1197.63</b>	<b>1207.28</b>	<b>1283.00</b>	<b>1207.28</b>	<b>1205.83</b>

**Notes:**

- The above results have been taken on record by the board of directors of the company at their meeting held on **13-02-2017**
- The financial results for the quarter ended 31-12-2016 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place : Hyderabad,  
Date : 13th February, 2017.

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Annexure V to Clause 41

Review Report to:

The Board of Directors,  
Trimurthi Limited  
Hyderabad.


We have reviewed the accompanying statement of unaudited financial results of **TRIMURTHI LIMITED** for the period ending **31<sup>st</sup> December, 2016**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS  
FRN: 000374S

PLACE: HYDERABAD  
DATE: 13.02.2017

  
K.VENKATESWARA RAO  
PROPRIETOR  
M.No. 200/29305

**Note 1.** The Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 and/or Accounting Standards issued by Institute of Chartered Accountants of India.



# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### LIMITED REVIEW REPORT

For the Quarter ended 31<sup>st</sup> December, 2016

To  
The Board of Directors,  
M/s TRIMURTHI LIMITED,  
Hyderabad.

We have reviewed the accompanying statement of unaudited Consolidated financial results of TRIMURTHI LIMITED ('the Holding company') and its Subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 31<sup>st</sup> December, 2016 ('the statement'), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 Dated 5<sup>th</sup> July, 2016. This Statement is the responsibility of the Holding Company's Management and approved by the Board of Directors/Committee of Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim financial reporting (Ind AS 34), Prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. The review is limited primarily to inquiries of Holding company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

This statement includes the results of the following entities:

Name of the Subsidiaries:

- i) Trimurthi Pharmaceuticals India Pvt Ltd.,
- ii) Trimurthi Foods Ltd.





# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the afore said Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , as modified by Circular No.CIR/CFD/FAC/62/2016 Dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS

FRN: 006374S

K.VENKATESWARA RAO  
PROPRIETOR

M.NO.27305

PLACE: HYDERABAD

Date: 13.02.2017

